Source: International Congress 2018 – Clinical aspects of hypersensitivity pneumonitis (HP) and CTD-ILD: diagnosis, monitoring and treatment
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. KAVOURA (ATHENS, Greece), A. Frimas (ATHENS, Greece), P. Kithreotis (ATHENS, Greece), C. Bagos (ATHENS, Greece), S. Kanellas (ATHENS, Greece), D. Veldekis (ATHENS, Greece). Clinical features of dermatitis, myositis and severe ILD. Could the  AntiSSA / Ro52 antibodies be a diagnostic and prognostic tool for Antisyntatase syndrom?. 2995

Member's Comments

No comment yet.

Related content which might interest you: Clinical and pathological findings of patients with interstitial lung diseases associated with antisynthetase other than Jo-1 antibodies Source: Eur Respir J 2005; 26: Suppl. 49, 541s Year: 2005 Clinical features and outcomes of patients with myositis associated-interstitial lung disease Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021 Severe sarcoidosis: clinical features and management Source: Virtual Congress 2021 – Rare lung diseases 2021 Year: 2021 Clinical features of patients with sarcoidosis associated with Sjogren‘s syndrome Source: Eur Respir J 2005; 26: Suppl. 49, 32s Year: 2005 Interstitial pneumonia with autoimmune features associated with myositis autoantibodies: clinical characteristics from a multicenter Latin-American cohort. Source: International Congress 2019 – Immune-mediated interstitial lung diseases: from bench to bedside Year: 2019 Utility of myositis related antibodies in interstitial lung disease and suspected autoimmunity. Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new? Year: 2019 Clinical significance of morphological indexes of inflammation and sclerosis in idiopathic fibrosing alveolitis (IFA) and lung sarcoidosis Source: Eur Respir J 2002; 20: Suppl. 38, 107s Year: 2002 Interstitial pneumonia with autoimmune features (IPAF): a clinical entity? Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis Year: 2019 Interstitial pneumonia with autoimmune features (IPAF): the relationship between radiological and clinical features Source: Virtual Congress 2020 – Clinical aspects of idiopathic pulmonary fibrosis Year: 2020 Clinical manifestations of neurological involvement in sarcoidosis - in our experience Source: Eur Respir J 2004; 24: Suppl. 48, 711s Year: 2004 Clinical features of interstitial lung disease in polymyositis and dermatomyositis Source: Eur Respir J 2006; 28: Suppl. 50, 828s Year: 2006 Undifferentiated systemic rheumatic diseases and overlap syndromes: when can we diagnose interstitial pneumonia with autoimmune features (IPAF)? Source: International Congress 2018 – Respiratory medicine meets rheumatology Year: 2018 Clinical features and CT findings of anti-Jo-1 antibody positive interstitial lung disease with or without polymyositis and dermatomyositis Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013 Idiopathic non-specific interstitial pneumonia (NSIP): is it an autoimmune clinical entity? Source: Annual Congress 2007 - Miscellaneous interstitial lung diseases related to systemic and other diseases Year: 2007 Interstitial pneumonia with autoimmune features: applying novel diagnostic criteria to an existing patient cohort. Source: International Congress 2017 – Novel and old entities Year: 2017 ANCA associated vasculitis – Evaluation of diagnosis, treatment and outcome in a group of 68 patients Source: International Congress 2014 – Clinical management of interstitial lung diseases and vasculitis Year: 2014 HLA-DRB1* alleles and symptoms associated with Heerfordt's syndrome in sarcoidosis Source: Eur Respir J 2011; 38: 1151-1157 Year: 2011 Clinical pearls and pitfalls Source: Annual Congress 2005 - Difficult asthma in children Year: 2005 Antinuclear antibodies and severe evolution of asthma Source: Annual Congress 2007 - Towards controlling severe asthma Year: 2007 Clinical utility of CCL15 as a prognostic biomarker for hypersensitivity pneumonitis Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new? Year: 2019